Applied DNA Sciences Inc
NASDAQ:BNBX
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| US |
|
Applied DNA Sciences Inc
NASDAQ:APDN
|
4m USD |
Loading...
|
|
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
1.1T USD |
Loading...
|
|
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
193.8B USD |
Loading...
|
|
| US |
|
Danaher Corp
NYSE:DHR
|
148.3B USD |
Loading...
|
|
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
136.5T KRW |
Loading...
|
|
| CH |
|
Lonza Group AG
SIX:LONN
|
36B CHF |
Loading...
|
|
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
286.8B CNY |
Loading...
|
|
| US |
|
Agilent Technologies Inc
NYSE:A
|
35.2B USD |
Loading...
|
|
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
28.1B USD |
Loading...
|
|
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
27.9B USD |
Loading...
|
|
| CN |
|
WuXi Biologics (Cayman) Inc
HKEX:2269
|
164.3B HKD |
Loading...
|
Market Distribution
| Min | -24 813% |
| 30th Percentile | 28.9% |
| Median | 43% |
| 70th Percentile | 60.5% |
| Max | 10 905 714.3% |
Other Profitability Ratios
Applied DNA Sciences Inc
Glance View
Applied DNA Sciences, Inc. engages in the developing and marketing DNA-based technology solutions utilizing LinearDNA, large-scale polymerase chain reaction (PCR) based manufacturing platform. The company is headquartered in Stony Brook, New York and currently employs 78 full-time employees. The company went IPO on 2001-08-24. The firm is utilizing its LinearDNA large-scale polymerase chain reaction (PCR) based manufacturing platform. The Company’s proprietary platform produces large quantities of DNA for use in the nucleic acid-based in vitro diagnostics and preclinical nucleic-acid based drug development and manufacturing markets and for supply chain security, anti-counterfeiting and anti-theft technology purposes. Applied DNA also develops PCR-based molecular in vitro diagnostics for covid-19. In addition, under its wholly owned subsidiary, Applied DNA Clinical Labs, LLC, the Company is offering a high-throughput turnkey solution for population-scale Covid-19 testing marketed as safeCircle. safeCircle utilizes the Company’s Covid-19 Diagnostic Tests and is designed to look for infection within defined populations or communities utilizing high throughput testing methodologies.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Applied DNA Sciences Inc is 39.6%, which is above its 3-year median of 35.6%.
Over the last 3 years, Applied DNA Sciences Inc’s Gross Margin has increased from 26.8% to 39.6%. During this period, it reached a low of 25% on Jun 30, 2024 and a high of 41.4% on Sep 30, 2023.
